Travere Therapeutics (TVTX) Competitors $21.98 -1.60 (-6.79%) Closing price 04:00 PM EasternExtended Trading$22.26 +0.27 (+1.25%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TVTX vs. RVMD, LEGN, BBIO, AXSM, BPMC, TLX, ELAN, LNTH, NUVL, and CYTKShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Revolution Medicines (RVMD), Legend Biotech (LEGN), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Elanco Animal Health (ELAN), Lantheus (LNTH), Nuvalent (NUVL), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Revolution Medicines Legend Biotech BridgeBio Pharma Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Elanco Animal Health Lantheus Nuvalent Cytokinetics Travere Therapeutics (NASDAQ:TVTX) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk. Does the MarketBeat Community favor TVTX or RVMD? Revolution Medicines received 9 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 75.83% of users gave Revolution Medicines an outperform vote while only 58.57% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes8258.57% Underperform Votes5841.43% Revolution MedicinesOutperform Votes9175.83% Underperform Votes2924.17% Do analysts rate TVTX or RVMD? Travere Therapeutics currently has a consensus target price of $27.77, indicating a potential upside of 17.77%. Revolution Medicines has a consensus target price of $66.25, indicating a potential upside of 56.77%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 Which has more risk & volatility, TVTX or RVMD? Travere Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Which has better valuation & earnings, TVTX or RVMD? Travere Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$203.45M9.05-$111.40M-$4.55-5.18Revolution Medicines$11.58M613.90-$436.37M-$3.59-11.77 Is TVTX or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to Travere Therapeutics' net margin of -172.75%. Revolution Medicines' return on equity of -33.67% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-172.75% -537.74% -55.65% Revolution Medicines N/A -33.67%-30.08% Does the media favor TVTX or RVMD? In the previous week, Travere Therapeutics had 6 more articles in the media than Revolution Medicines. MarketBeat recorded 9 mentions for Travere Therapeutics and 3 mentions for Revolution Medicines. Travere Therapeutics' average media sentiment score of 0.74 beat Revolution Medicines' score of 0.46 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in TVTX or RVMD? 94.3% of Revolution Medicines shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 8.0% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryRevolution Medicines beats Travere Therapeutics on 13 of the 18 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.84B$7.02B$5.84B$9.20BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-5.182.6016.3214.14Price / Sales9.05320.96461.0479.70Price / CashN/A67.8344.0437.47Price / Book8.836.837.794.78Net Income-$111.40M$138.11M$3.18B$245.88M7 Day Performance2.92%-0.79%-0.52%-0.90%1 Month Performance21.17%-0.17%1.80%-0.52%1 Year Performance199.24%-1.82%18.90%16.50% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.9887 of 5 stars$21.98-6.8%$27.77+26.3%+184.8%$1.72B$203.45M-4.83460Earnings ReportAnalyst ForecastGap DownRVMDRevolution Medicines4.5192 of 5 stars$40.67-1.6%$66.25+62.9%+44.9%$6.84B$11.58M-11.33250Positive NewsLEGNLegend Biotech2.6195 of 5 stars$36.42+0.1%$79.50+118.3%-35.2%$6.65B$285.14M-38.341,800Positive NewsGap UpBBIOBridgeBio Pharma4.7364 of 5 stars$34.90+10.6%$49.08+40.6%+2.4%$6.60B$9.30M-14.48400Earnings ReportAnalyst ForecastInsider TradeNews CoverageGap UpAXSMAxsome Therapeutics4.5395 of 5 stars$131.15-0.4%$147.13+12.2%+59.2%$6.36B$270.60M-20.08380Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageBPMCBlueprint Medicines3.0196 of 5 stars$93.94-1.3%$123.83+31.8%+3.4%$5.97B$249.38M-44.52640Earnings ReportTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.19-0.6%$22.00+28.0%N/A$5.79B$637.08M0.00N/ANews CoverageGap UpELANElanco Animal Health4.1542 of 5 stars$11.26-3.4%$16.29+44.7%-31.0%$5.57B$4.42B28.159,300Analyst ForecastLNTHLantheus4.588 of 5 stars$79.94-2.5%$131.86+64.9%+42.3%$5.56B$1.30B13.30700Analyst RevisionPositive NewsNUVLNuvalent2.126 of 5 stars$77.93-3.7%$112.36+44.2%+0.5%$5.54BN/A-22.4640Upcoming EarningsInsider TradeCYTKCytokinetics4.1946 of 5 stars$46.16+10.9%$82.00+77.6%-33.5%$5.45B$7.53M-8.58250High Trading Volume Related Companies and Tools Related Companies Revolution Medicines Competitors Legend Biotech Competitors BridgeBio Pharma Competitors Axsome Therapeutics Competitors Blueprint Medicines Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Elanco Animal Health Competitors Lantheus Competitors Nuvalent Competitors Cytokinetics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TVTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
